Multiple studies (retrospective, survey's and non interventionnal)

Retrospective study on the role of CD8+ T cells in haematopoietic stem cell transplantation (HSC-T)

Conclusions and perspectives

Apoptosis in mesenchymal stromal cells induces differential immune modulation.

Tribute to Jon van Rood and Jon van Rood

More than hundred papers written with Jon van Rood in haematopoietic transplantation.

Current observations and implementation of cell therapy approaches to improve post-transplantation outcomes. The CTIWP aims at fostering cellular therapy in Europe, through a continuous crosstalk between basic science findings, transplant immunobiology observations and implementation of cell therapy approaches to answer unmet medical needs.

Science:

- Multiple studies (retrospective, survey’s and non interventionnal)
- 15 abstracts

Education 2017:
The 2nd CTIWP Scientific Symposium
January 18-20, 2018, Leiden, The Netherlands

Cellular Therapy Registry

The Cellular Therapy Registry (CTR) aims to collect in-depth knowledge on the nature of stem cell, progenitor or mature cell products, including immune cells, either minimally manipulated such as DLI or substantially processed such as sorted, cultured or genetically manipulated lymphocytes, including CAR-T cells, used for treatment in combination with hematopoietic stem cell transplantation or alone, and including advanced therapeutic medicinal products (ATMP). The new format will allow for collection of data on the clinical characteristics and outcome of the patients. Currently 5823 cases are recorded in the EBMT database: these include mostly DLI’S (5446) and +/- 8 patients with engineered and vector modified cells.

PLease CONTRIBUTe...and REGISTER YOUR PATIENTS!!

The new format and manual are now available at www.ebmt.org in the following section:
Data Management > Registry structure > Data collection forms & manuals

Currently working on wide implementation of this newly-created MED B form, to be used as a platform for collaboration with different Pharma companies that develop and market or plan to market somatic cell therapy or gene therapy medicinal products (PASS studies). Discussions are underway with EU competent authorities and commission as well as with interested Pharma partners.

CTIWP Mission

Mission:

To understand and exploit the biological including immunological events occurring upon HSCT at large, and to implement modern cellular therapies based on cell and gene engineering approaches to improve post-transplantation outcomes.

Respectively:

- Retrospective study in medastinal Germ Cell Tumours (G. Rosti)
- Retrospective study on T cell in adult solid tissue sarcoma (Christoph E. Heilig)
- Long-term survival in patients with metastatic breast cancer receiving high-dose chemotherapy and autologous hematopoietic stem cell transplantation (M. Maritono)
- Stem cell transplantation in Ewing’s sarcoma (PNET) (Christoph E. Heilig, et al.)

Review articles

- Please write on T cell therapy for solid tumors (P. Comolli)
- Review article on Hematopoietic Stem Cell Transplantation in its 60s: a platform for cellular therapies (C. Chabannon, C. Bonini and all subcommittee leaders), recently accepted for publication in Translational Medicine.

Survey’s

- Manufacturing of Mesenchymal Stromal Cells for the treatment of Graft-versus-Host Disease: a Survey within the European Society of Blood and Marrow Transplantation (F. Dazzi)

Closed Studies / Studies in analysis

- Beneficial role of CD8+ T-cell reconstitution after HLA-haploidentical stem cell transplantation for high-risk leukemia: results from a clinico-biological EBMT registry study (A. Bonandza)
- Manuscript in revision
- Immuno-Monitoring in Allogeneic Hematopoietic Stem Cell Transplant Recipients: a Survey from the EBMT - CTIWP (R. Greco), Manuscript in revision
- The role of parent-child and sibling/sibling immune interactions (Inherited Paternal vs Non-inherited Maternal Antigens) in clinical outcomes after haploidentical transplantation for leukemia under diverse protocols (A. Velardi), Manuscript in preparation
- Handling, processing and disposal of stem cell products in Europe: a Survey by the CTIWP of the EBMT (A Holberg). Results published in Cytotherapy, 2018

Key Publications 2017

Single- or double-unit UCBT following RIC in adults with A: a report from Eurocord, the ALLUP and the CTIWP of the EBMT.


Long-Term Results of Cord Blood Transplantation from an HLA-identical Sibling for Patients with Bone Marrow Failure Syndromes: A Report From Eurocord, CTIWP Committee and Severe Aplastic Anemia Working Party of European Society for Blood and Marrow Transplantation.


A risk factor analysis of outcomes after unrelated cord blood transplantation for children with Wiskott-Aldrich syndrome.


Eurocord, Cord Blood Committee of Cellular Therapy and Immunobiology Working Party of the EBMT, Federal University of Paraná, Duke University Medical Center and PTB of the EBMT.


Impact of CTLA4 genotype and other immune gene polymorphisms on outcomes after single umbilical cord blood transplantation.


Salvage High-Dose Chemotherapy for Relapsed Pure S Tuma lignoma in the Last 10 Years: Results from the European Society for Blood and Marrow Transplantation Series 2002-2012.


Salvage high-dose chemotherapy in female patients with relapsed/refractory germ-cell tumors: a retrospective analysis of the European group for Blood and Marrow Transplantation (EBMT)


Administration of high-dose chemotherapy with stem cell support in patients 40 years of age or older with advanced germ cell tumors: a retrospective study from the European Society for Blood and Marrow Transplantation database.

A Necchi, S Lo Volo, G Ross, M Badoglio, P Giannatempo, D Rajj, S Secondino, J Mariani, F Lanzo, P Pedrazzoli.


Secondary malignancies after high-dose chemotherapy in germ cell tumour patients: a 34-year retrospective study from the European Society for Blood and Marrow Transplantation (EBMT).

A Necchi, A L, Pedrazzoli, P EBMT, CTIWP, Solid Tumour sub-committee.

Bone Marrow Transplantation. 2018 Jan 24. doi: 10.1038/s41409-017-0072-y. [Epub ahead of print] PMID: 29067713

Contact

For participation in, or information on CTIWP studies, please contact the CTIWP

Technical Support
Jumilng Wang
www.ume.org

Cells Therapy &
Immunobiology Working Party
Chair: Chiara Bonini
Subcommittee Leaders:
Immune Tolerance: Francesco Dazzi
Cancer Immunotherapy: Attilio Bondanza
Immunogenetics: Katharina Fleischhauer & Vanderson Rocha
Secretary: Christian Chabannon
Cord Blood Immunology: Annalisa Ruggieri
Transplant Immunology: Antoine Toubert
Solid tumours: Paolo Pedrazzoli

Please vote in the election of the next CTIWP Chair

The role of Donor vs. recipient NK cell allo-reactivity in haploidentical hematopoietic transplantation for AML and ALL

Pr: Andrea Medeiros and Ludmila Ruggieri

Donor versus recipient NK cell allo-reactivity is a key therapeutic element in the success of HLA haplotype mismatched ("haploidentical") HSCT’s for acute myeloid leukemia. We performed a non-interventional, prospective study on the role of NK cell alloreactivity in haploidentical transplantation performed under a variety of protocols that included T cell depletion as well as unmanipulated grafts.

*Participating centres please send in your follow up data *

Presented in detail in an oral session (Room 5A)

Wednesday, March 21st, 11:40-11:50